A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
This study will evaluate the efficacy of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF subjects).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply
St. Petersburg, Florida 33701, United States
Niles, Illinois 60714, United States
Indianapolis, Indiana 46202, United States
St Louis, Missouri 63110, United States
Buffalo, New York 14222, United States
Philadelphia, Pennsylvania 19017, United States
Pittsburgh, Pennsylvania 15224, United States
Knoxville, Tennessee 37920, United States
Memphis, Tennessee 38103, United States
Jena, Germany
Newcastle upon Tyne, United Kingdom